Lee DM, Weinblatt ME: Rheumatoid arthritis. Lancet. 2001, 358: 903-911. 10.1016/S0140-6736(01)06075-5.
Article
PubMed
CAS
Google Scholar
Spector TD: Rheumatoid arthritis. Rheum Dis Clin North Am. 1990, 16: 513-537.
PubMed
CAS
Google Scholar
Silman AJ, Pearson JE: Epidemiology and genetics of rheumatoid arthritis. Arthritis Res. 2002, 4 (Suppl 3): S265-S272. 10.1186/ar578.
Article
PubMed Central
PubMed
Google Scholar
Mikuls TR, Saag KG, Criswell LA, Merlino LA, Kaslow RA, Shelton BJ, Cerhan JR: Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa Women's Health Study. Ann Rheum Dis. 2002, 61: 994-999. 10.1136/ard.61.11.994.
Article
PubMed Central
PubMed
CAS
Google Scholar
Lapsley HM, March LM, Tribe KL, Cross MJ, Courtenay BG, Brooks PM: Living with rheumatoid arthritis: expenditures, health status, and social impact on patients. Ann Rheum Dis. 2002, 61: 818-821. 10.1136/ard.61.9.818.
Article
PubMed Central
PubMed
CAS
Google Scholar
American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines: Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum. 2002, 46: 328-346. 10.1002/art.10148.
Article
Google Scholar
Wolfe F, Cush JJ, O'Dell JR, Kavanaugh A, Kremer JM, Lane NE, Moreland LW, Paulus HE, Pincus T, Russell AS, Wilskie KR: Consensus recommendations for the assessment and treatment of rheumatoid arthritis. J Rheumatol. 2001, 28: 1423-1430.
PubMed
CAS
Google Scholar
Emery P, Reginster JY, Appelboom T, Breedveld FC, Edelmann E, Kekow J, Malaise M, Mola EM, Montecucco C, Sanda M, Sany J, Scott DL, Serni U, Seydoux G: WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis. Rheumatology (Oxford). 2001, 40: 699-702. 10.1093/rheumatology/40.6.699.
Article
CAS
Google Scholar
Maetzel A, Tugwell P, Boers M, Guillemin F, Coyle D, Drummond M, Wong JB, Gabriel SE: Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case. J Rheumatol. 2003, 30: 891-896.
PubMed
Google Scholar
Emery P: Is it time for a European consensus on the pharmacological management of early RA?. J Rheumatol Suppl. 2002, 66: 1-2.
PubMed
Google Scholar
Eigler A, Sinha B, Hartmann G, Endres S: Taming TNF: strategies to restrain this proinflammatory cytokine. Immunol Today. 1997, 18: 487-492. 10.1016/S0167-5699(97)01118-3.
Article
PubMed
CAS
Google Scholar
Brennan FM, Maini RN, Feldmann M: TNF alpha – a pivotal role in rheumatoid arthritis?. Br J Rheumatol. 1992, 31: 293-298.
Article
PubMed
CAS
Google Scholar
Feldmann M: What is the mechanism of action of anti-tumour necrosis factor-α antibody in rheumatoid arthritis?. Int Arch Allergy Immunol. 1996, 111: 362-365.
Article
PubMed
CAS
Google Scholar
Maini RN, Feldmann M: How does infliximab work in rheumatoid arthritis?. Arthritis Res. 2002, 4 (Suppl 2): S22-S28. 10.1186/ar549.
Article
PubMed Central
PubMed
Google Scholar
Medical Economics Company Inc: Prescribing information: Enbrel®. In Physicians' Desk Reference®. 2002, Montvale, NJ, 3504-3507.
Google Scholar
Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer MB, Blosch CM: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997, 337: 141-147. 10.1056/NEJM199707173370301.
Article
PubMed
CAS
Google Scholar
Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, Furst D, Goldsmith C, Kieszak S, Lightfoot R, (The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials): The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum. 1993, 36: 729-740.
Article
PubMed
CAS
Google Scholar
Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleis-chmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, Ruderman EM, Horwitz DA, Arkfeld DG, Garrison L, Burge DJ, Blosch CM, Lange MLM, McDonnell ND, Weinblatt ME: Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999, 130: 478-486.
Article
PubMed
CAS
Google Scholar
Moreland LW, Cohen SB, Baumgartner SW, Schiff MH, Tindall EA, Burge DJ: Long-term use of Enbrel® (etanercept) in patients with DMARD-refractory rheumatoid arthritis. Presented at the 2nd Annual European Congress of Rheumatology (EULAR). 2001, , Prague, the Czech Republic, on 15 June 2001.
Google Scholar
Moreland LW, Cohen S, Fleischmann RM, Baumgartner SW, Schiff MH, Burge DJ: Safety and efficacy of up to 5 years of etanercept (Enbrel®) therapy in rheumatoid arthritis. Presented at the 3rd Annual European Congress of Rheumatology (EULAR). 2002, , Stockholm, Sweden, on 14 June 2002.
Google Scholar
Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999, 340: 253-259. 10.1056/NEJM199901283400401.
Article
PubMed
CAS
Google Scholar
Kremer JM, Weinblatt ME, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Jackson CG, Atkins KM, Feng A, Burge DJ: Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations. Arthritis Rheum. 2003, 48: 1493-1499. 10.1002/art.11142.
Article
PubMed
CAS
Google Scholar
Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Finck BK: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000, 343: 1586-1593. 10.1056/NEJM200011303432201.
Article
PubMed
CAS
Google Scholar
Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Cannon GW, Spencer-Green G, Finck BK: Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002, 46: 1443-1450. 10.1002/art.10308.
Article
PubMed
CAS
Google Scholar
Plant MJ, Saklatvala J, Borg AA, Jones PW, Dawes PT: Measurement and prediction of radiological progression in early rheumatoid arthritis. J Rheumatol. 1994, 21: 1808-1813.
PubMed
CAS
Google Scholar
Sharp JT: Scoring radiographic abnormalities in rheumatoid arthritis. Radiol Clin North Am. 1996, 34: 233-241.
PubMed
CAS
Google Scholar
Van Der Heijde D, Simon L, Smolen J, Strand V, Sharp J, Boers M, Breedveld F, Weisman M, Weinblatt M, Rau R, Lipsky P: How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion. Arthritis Rheum. 2002, 47: 215-218. 10.1002/art.10181.
Article
PubMed
Google Scholar
Genovese M, Martin RW, Fleischmann R, Keystone E, Bathon J, Spencer-Green G, Finck B: Enbrel® (etanercept) vs. methotrexate (MTX) in early rheumatoid arthritis (ERA trial): two-year follow up. Presented at the 2nd Annual European Congress of Rheumatology (EULAR). 2001, , Prague, the Czech Republic, on 16 June 2001.
Google Scholar
Wells GA, Tugwell P, Kraag GR, Baker PRA, Groh J, Redelmeier DA: Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol. 1993, 20: 557-560.
PubMed
CAS
Google Scholar
Fleischmann R, Baumgartner S, Moreland L, Schiff M, Markenson J, Spencer-Green G: Improvement of disability in RA patients with early vs established disease after treatment with Enbrel® (etanercept). Presented at the 2nd Annual European Congress of Rheumatology (EULAR). 2001, , Prague, the Czech Republic, on 15 June 2001.
Google Scholar
Abbott Laboratories: Humira: package insert. 2002, Abbott Park, IL
Google Scholar
de Putte LBA, Rau R, Breedveld FC, Kalden JR, Malaise MG, van Riel PLCM, Schattenkirchner M, Emery P, Burmester GR, Zeidler H, Montsopoulos HM, Beck K, Kupper H: Efficacy and safety of the fully human anti-tumour necrosis factor α monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis. 2003, 62: 1168-1177. 10.1136/ard.2003.009563.
Article
Google Scholar
Keystone E, Weinblatt ME, Weisman M, Furst D, Paulus H, Birbara C, Fischkoff S, Chartash EK: The fully human anti-TNF monoclonal antibody, adalimumab (D2E7), dose ranging study: the 24-week clinical results in patients with active RA on methotrexate (the ARMADA trial). Presented at the 2nd Annual European Congress of Rheumatology (EULAR). 2001, , Prague, the Czech Republic, on 15 June 2001.
Google Scholar
Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK: Adalimumab, a fully human anti-tumor necrosis factor alpha mono-clonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003, 48: 35-45. 10.1002/art.10697.
Article
PubMed
CAS
Google Scholar
Kavanaugh AF, Weinblatt M, Keystone E, Furst DE, Moreland LW, Teoh L, Fischkoff S, Chartash E: The ARMADA trial: 12-month efficacy and safety of combination therapy with adalimumab (D2E7), the first fully human anti-TNF monoclonal antibody, and methotrexate (MTX) in patients with active rheumatoid arthritis. Presented at the 3rd Annual European Congress of Rheumatology (EULAR). 2002, , Stockholm, Sweden, on 14 June 2002.
Google Scholar
Keystone E, Kavanaugh AF, Sharp J, Hua Y, Teoh L, Fischkoff S, Chartash E: Adalimumab (D2E7), a fully human anti-TNF-α monoclonal antibody, inhibits the progression of structural joint damage in patients with active RA despite concomitant methotrexate therapy. Arthritis Rheum. 2002, 46 (9 Suppl): S205-
Google Scholar
Centocor, Inc.: Remicade: package insert, revised June 2002. 2002, Malvern, PA
Google Scholar
Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, Wagner C: Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther. 2002, 301: 418-426. 10.1124/jpet.301.2.418.
Article
PubMed
CAS
Google Scholar
Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P, for the ATTRACT Study Group: Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet. 1999, 354: 1932-1939. 10.1016/S0140-6736(99)05246-0.
Article
PubMed
CAS
Google Scholar
Lipsky PE, van der Heijde DMFM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN, for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis With Concomitant Therapy Study Group: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000, 343: 1594-1602. 10.1056/NEJM200011303432202.
Article
PubMed
CAS
Google Scholar
Lipsky P, van der Heijde D, St Clair W, Furst D, Kalden J, Weisman M, Breedveld F, Emery P, Keystone E, Harriman G, Maini R: The ATTRACT Investigators. 102-week clinical and radiologic results from the ATTRACT trial: a 2-year, randomized, controlled, phase 3 trial of infliximab (Remicade®) in patients with active RA despite MTX. Arthritis Rheum. 2000, 43 (Suppl 9): 1216-
Google Scholar
Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J, Woody JN: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum. 1993, 36: 1681-1690.
Article
PubMed
CAS
Google Scholar
Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, Woody JN: Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet. 1994, 344: 1125-1127. 10.1016/S0140-6736(94)90632-7.
Article
PubMed
CAS
Google Scholar
Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, Woody JN: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994, 344: 1105-1110. 10.1016/S0140-6736(94)90628-9.
Article
PubMed
CAS
Google Scholar
Kavanaugh A, St Clair EW, McCune WJ, Braakman T, Lipsky P: Chimeric anti-tumor necrosis factor-α monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol. 2000, 27: 841-850.
PubMed
CAS
Google Scholar
Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfar-lane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998, 41: 1552-1563. 10.1002/1529-0131(199803)41:3<565::AID-ART28>3.3.CO;2-#.
Article
PubMed
CAS
Google Scholar
Allaire SH, Prashker MJ, Meenan RF: The costs of rheumatoid arthritis. Pharmacoeconomics. 1994, 6: 513-522.
Article
PubMed
CAS
Google Scholar